title: Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model.
abstract: The ratio of von Willebrand factor (VWF) to FVIII differs among available VWF/FVIII concentrates. Repeated infusions of concentrates with a low VWF:FVIII ratio may expose patients with von Willebrand disease to supranormal FVIII levels. The aim of this study was to determine the effects of repeated infusions with two VWF/FVIII concentrates differing in VWF:FVIII ratio on attained FVIII trough and peak levels as well as other pharmacokinetic parameters. Rabbits were randomized to receive multiple 150 IU kg⁻¹ VWF:RCo infusions at 4 h intervals with VWF/FVIII concentrates of a high (Haemate® P/Humate-P®) or low (Wilate®) VWF:FVIII ratio. Trough plasma FVIII and VWF levels were measured after each infusion. Pharmacokinetic analysis was performed using samples collected frequently after infusion. Mean FVIII trough level after the first Wilate infusion was 50.6 IU dL⁻¹ with a 95% confidence interval (CI) of 43.1-58.2 IU dL⁻¹, compared with 31.8 IU dL⁻¹ (CI, 24.4-39.1 IU dL⁻¹) for Haemate P (P<0.001). Trough levels progressively increased over the 24 h treatment period in both groups. After the final infusion, mean trough FVIII remained significantly higher (P = 0.002) in recipients of Wilate. Mean peak FVIII concentration after infusion was 67% higher in the Wilate group (167 vs. 100 IU dL⁻¹ , respectively; P = 0.002). Mean cumulative exposure to FVIII, as measured by area under the curve, was 84% greater in Wilate-treated animals. Half-life did not differ between the two concentrates. Animal model data suggest that exposure to elevated FVIII levels can be reduced through use of VWF/FVIII concentrates with higher VWF:FVIII ratios.
authors: Departments of Preclinical Research and Development Medical Affairs, Commercial Development Coagulation, CSL Behring GmbH, Marburg, Germany.
authors: E
authors: E
authors: Raquet
authors: M
authors: M
authors: Stockschläder
authors: G
authors: G
authors: Dickneite
mesh_terms: D000818:Animals; D019540:Area Under Curve; D003029:Coagulants / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D004338:Drug Combinations; D005169:Factor VIII / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D005260:Female; D006207:Half-Life; D007262:Infusions, Intravenous; D023421:Models, Animal; D011817:Rabbits; D014841:von Willebrand Factor / Q000008:administration & dosage* / Q000493:pharmacokinetics*
chemical_list: D003029:Coagulants; D004338:Drug Combinations; C509423:factor VIII, von Willebrand factor drug combination; D014841:von Willebrand Factor; D005169:Factor VIII